^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Solid Tumor
    Drug:Torisel (temsirolimus) (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Erlotinib and Temsirolimus for Solid Tumors

    Excerpt:
    ...- Tumor Mutational Status (Dose Expansion Phase ONLY): Patients must have tumor harboring PTEN loss, PIK3CA mutation, , and/or EGFR mutation....
    Trial ID:
    NCT00770263
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

    Excerpt:
    ...- Tissue must demonstrate mTOR+: PTEN loss OR PIK3C2B or AKT3 amplification on aCGH OR mutations for PIK3CA or PIK3R1, or mTOR or PTEN mutations using next-generation sequencing analysis OR pS6 positivity on immunohistochemistry (≥30% for pS6)....
    Trial ID:
    NCT05773326
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

    Published date:
    05/25/2023
    Excerpt:
    Although T does not appear to have antitumor activity in pts with BC with PIK3CA mut, it does show antitumor activity in pts with other solid tumors with PIK3CA mut and warrants further study. 
    DOI:
    10.1200/JCO.2023.41.16_suppl.3117
    Trial ID:
    TAPUR